Index | ROBO Global Healthcare Technology and Innovation |
Investment focus | Equity, World, Health Care |
Fund size | GBP 56 m |
Total expense ratio | 0.49% p.a. |
Replication | Physical (Full replication) |
Legal structure | ETF |
Strategy risk | Long-only |
Sustainability | No |
Fund currency | USD |
Currency risk | Currency unhedged |
Volatility 1 year (in GBP) | 57.98% |
Inception/ Listing Date | 2 July 2019 |
Distribution policy | Accumulating |
Distribution frequency | - |
Fund domicile | Ireland |
Fund Provider | Legal & General (LGIM) |
Fund Structure | Open-ended Investment Company (OEIC) |
UCITS compliance | Yes |
Administrator | BNY Mellon Fund Services (Ireland) Designated Activity Company |
Investment Advisor | Legal & General Investment Management Limited |
Custodian Bank | BNY Mellon Trust Company (Ireland) Limited |
Revision Company | EY |
Fiscal Year End | 30 June |
Swiss representative | State Street |
Swiss paying agent | State Street Bank International GmbH, München, Zweigniederlassung Zürich |
Germany | 30% tax rebate |
Switzerland | No ESTV Reporting |
Austria | Tax Reporting Fund |
UK | UK Reporting |
Indextype | Total return index |
Swap counterparty | - |
Collateral manager | BNY Mellon Fund Services (Ireland) Limited |
Securities lending | No |
Securities lending counterparty |
AxoGen | 2.15% |
Danaher Corp. | 1.96% |
Boston Scientific Corp. | 1.93% |
Thermo Fisher Scientific, Inc. | 1.92% |
Charles River Labs Intl | 1.89% |
Intuitive Surgical | 1.84% |
Azenta | 1.82% |
Stryker | 1.81% |
Natera | 1.80% |
STAAR Surgical | 1.79% |
Health Care | 91.82% |
Technology | 1.46% |
Consumer Discretionary | 1.42% |
Other | 5.30% |
YTD | +8.18% |
1 month | +6.17% |
3 months | +7.72% |
6 months | +12.66% |
1 year | +12.66% |
3 years | -8.83% |
5 years | +17.94% |
Since inception (MAX) | +32.31% |
2024 | +4.61% |
2023 | -8.06% |
2022 | -25.30% |
2021 | +1.45% |
Volatility 1 year | 57.98% |
Volatility 3 years | 40.22% |
Volatility 5 years | 35.68% |
Return per risk 1 year | 0.22 |
Return per risk 3 years | -0.08 |
Return per risk 5 years | 0.09 |
Maximum drawdown 1 year | -25.45% |
Maximum drawdown 3 years | -36.31% |
Maximum drawdown 5 years | -51.17% |
Maximum drawdown since inception | -51.17% |
Listing | Trade Currency | Ticker | Bloomberg / iNAV Bloomberg Code | Reuters RIC / iNAV Reuters | Market Maker |
---|---|---|---|---|---|
gettex | EUR | XMLH | - - | - - | - |
Borsa Italiana | EUR | DOCT | DOCT IM DOCEURIV | DOCT.MI DOCTEURINAV=SOLA | Flow Traders B.V. |
London Stock Exchange | GBX | DOCG | DOCG LN NA | DOCG.L NA | Flow Traders B.V. |
London Stock Exchange | USD | DOCT | DOCT LN NA | DOCT.L NA | Flow Traders B.V. |
SIX Swiss Exchange | CHF | DOCT | DOCT SW DOCEURIV | DOCT.S | Flow Traders B.V. |
XETRA | EUR | XMLH | XMLH GY DOCEURIV | DOCT.DE | Flow Traders B.V. |
Fund name | Fund Size in m € (AuM) | TER p.a. | Distribution | Replication |
---|---|---|---|---|
iShares Healthcare Innovation UCITS ETF | 1,039 | 0.40% p.a. | Accumulating | Sampling |
L&G Pharma Breakthrough UCITS ETF | 18 | 0.49% p.a. | Accumulating | Full replication |
Harbor Health Care UCITS ETF Accumulating | 15 | 0.89% p.a. | Accumulating | Full replication |
VanEck Genomics and Healthcare Innovators UCITS ETF A | 5 | 0.35% p.a. | Accumulating | Full replication |
Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C | 4 | 0.30% p.a. | Accumulating | Full replication |